GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » Net Interest Income (for Banks)

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Net Interest Income (for Banks)


View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.